Journal: Bioactive Materials

Article Title: A catalytically active and recyclable bioelastomer inspired by metalloenzymes

doi: 10.1016/j.bioactmat.2026.02.053

Figure Lengend Snippet: Host responses to mouse subcutaneous implantation of Cu-PIAS. ( A ) Representative hematoxylin and eosin staining of the implant site after 7, 14, and 21 days. 25-Cu-PIAS mesh is roughly centered in each image and runs horizontally. Mesh material stains homogenously red and is indicated by arrows in the leftmost image of each timepoint. ( B ) Area of 25-Cu-PIAS mesh at each timepoint. Reduction over time indicates degradation of material. ( C ) Blood vessel density around and within the implant sites (CD31 immunohistochemistry) at each timepoint. ( D ) Total macrophage density around and within the implant sites (F4/80 immunohistochemistry) at each timepoint. ( E ) M2 macrophage density around and within the implant sites (CD163 immunohistochemistry) at each timepoint. ( F ) Ratio of macrophages expressing a M2 phenotype at each timepoint. ( G ) Collagen thickness above the implant site of scarring mouse model (CXCR3 −/− ), comparing responses to 15-Cu-PIAS and fibrin gel after 3 and 6 months. Statistics: ∗, ∗∗, ∗∗∗, and ∗∗∗∗ indicate p ≤ 0.05, 0.01, 0.001, and 0.0001, respectively.

Article Snippet: F4/80 antibody was purchased from Cell Signaling Technology (Danvers MA, Cat #: 70076).

Techniques: Staining, Immunohistochemistry, Expressing

Journal: Frontiers in Immunology

Article Title: Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer

doi: 10.3389/fimmu.2026.1866073

Figure Lengend Snippet: LILRB4 is associated with macrophages in the OC immune microenvironment. (A) Correlation of StromalScore, ImmuneScore, and ESTIMATEScore with LILRB4 expression in TCGA-OV patients. (B) UMAP visualization of single-cell RNA-seq data from the OV_EMTAB8107 tumor dataset (left) and corresponding LILRB4 expression across different cell clusters (right). (C) Distribution of LILRB4 expression across various cell types in GEO-derived single-cell datasets, analyzed using the TISCH2 database ( http://tisch.comp-genomics.org/ ), with darker colors indicating higher expression levels. (D) Correlation between macrophage enrichment scores and LILRB4 expression in TCGA-OV samples, as determined by ssGSEA. (E) Relative mRNA expression of F4/80 in orthotopic ovarian tumor models (NC and sh-LILRB4 groups). (F) Representative IHC images showing F4/80 expression in orthotopic ovarian tumors (n = 3). Scale bar, 100 μm. (G) Representative IHC staining of CD68 and LILRB4 in corresponding regions of human OC tissues (n = 3). All panels are shown at the same magnification. Scale bar, 100 μm. Data are presented as mean ± SD. Statistical analysis was performed using unpaired two-tailed Student’s t-test. *p < 0.05, ****p < 0.0001.

Article Snippet: All antibodies used in this study were commercially available: LILRB4 (A7073; ABclonal, Wuhan, China; 1:2000 for WB and 1:200 for immunohistochemistry), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (AB2100; NCM Biotech, Suzhou, China; 1:20,000), F4/80 (A27257; ABclonal, Wuhan, China; 1:200), Ki67 (A20018; ABclonal, Wuhan, China; 1:200), CD68 (A24386PM; ABclonal, Wuhan, China; 1:200), phospho-NF-κB (p-NF-κB; TP56372; Abmart, Shanghai, China; 1:1000), CD163 (A8383SP; ABclonal, Wuhan, China; 1:200), CD8 (A23081; ABclonal, Wuhan, China; 1:200), granzyme B (GZMB) (A2557; ABclonal, Wuhan, China; 1:200), and goat anti-rabbit IgG (H+L)-HRP conjugate (LF102; Epizyme Biotech, Shanghai, China; 1:3000).

Techniques: Expressing, Single Cell, RNA Sequencing, Derivative Assay, Immunohistochemistry, Two Tailed Test